| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5284b3a2390cf8c8ec2c213f9ffdd957
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b5595fd5013df41242d6af668fef561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6cf7b8e451f435800775cccba925dda5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_927d2826ecfd4c14d6a2b7c5604be274 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-285
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-28 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate |
2019-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efdd949d4d19022d59cb4872e69ede0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e9f00cff9b10df6a6dc130be1028e73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea2131f9885ae8aa4b2e3855058cabf8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ff9925751681430edeb956b75046f7b9 |
| publicationDate |
2020-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3721896-A1 |
| titleOfInvention |
Epidermal growth factor (egf) and variants thereof for medical uses in neuro-de/regeneration |
| abstract |
The present invention relates to a (poly)peptide having Epidermal Growth Factor (EGF)-activity or a nucleic acid encoding said (poly)peptide for use in treating or preventing a demyelinating and/or neurodegenerating disorder, wherein the (poly)peptide (a) comprises or consists of the amino acid sequence of SEQ ID NO: 1; and/or (b) comprises or consists of an amino acid sequence, which is at least 66% identical to the amino acid sequence of SEQ ID NO: 1; and/or (c) comprises or consists of a fragment of (a) or (b); and wherein the (poly)peptide or nucleic acid is the only pharmaceutically active agent to be administered. |
| priorityDate |
2019-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |